{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:36:59Z","timestamp":1779219419233,"version":"3.51.4"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jcf.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:43:53Z","timestamp":1608165833000},"page":"195-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-386X","authenticated-orcid":false,"given":"Kelsie","family":"Pearson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Z.","family":"Retsch-Bogart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"VanDalfsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-4941","authenticated-orcid":false,"given":"Patricia","family":"Burks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rosenbluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2020.12.007_bib0001","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","article-title":"Impact of COVID-19 on oncology clinical trials","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2020.12.007_bib0002","article-title":"The impact of COVID-19 on dermatology clinical trials","author":"Desai","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jcf.2020.12.007_bib0003","first-page":"56","article-title":"SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network","author":"van Koningsbruggen-Rietschel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2020.12.007_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcf.2020.04.012","article-title":"A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis","volume":"19","author":"Cosgriff","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2020.12.007_bib0005","year":"2020"},{"key":"10.1016\/j.jcf.2020.12.007_bib0006","doi-asserted-by":"crossref","unstructured":"Pasnick S., Carlos W.G., Dela Cruz C.S., Gross J.E., Garrison G., Jamil S. SARS-CoV-2 Transmission and the Risk of Aerosol Generating Procedures. 2020 Jun 30. Available from: https:\/\/www.thoracic.org\/patients\/patient-resources\/resources\/aerosol-generating-procedures-and-risk-of-covid-19-transmission.pdf.","DOI":"10.1164\/rccm.2020C11"},{"key":"10.1016\/j.jcf.2020.12.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2020.10.003","article-title":"The global impact of SARS-CoV-2 in 181 people with cystic fibrosis","author":"McClenaghan","year":"2020","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320309395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320309395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:43:21Z","timestamp":1761601401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320309395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1569199320309395"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.12.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}